Oncology

Review top news and interview highlights from the week ending May 6, 2022.

Radek Špíšek, PhD, co-founder and chief executive officer of SOTIO Global, and Geoffrey Hodge, chief executive officer of SOTIO BioTech US, join CGTL to discuss its 3 technology platforms and how they are leveraging them to attack the solid tumor micro-environment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

There was a continued trend toward improvement of overall survival with omidubicel at 73% compared with UCBT at 60%.

Rami Elghandour, chairman and CEO of Arcellx, shares updates on the phase 1 trial of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.

Review top news and interview highlights from the week ending April 29, 2022.

The real-world analysis addresses a clear gap in data from previous and ongoing cell therapy clinical trials.

Several CAR T-cell therapies have proved to be efficacious in hematological malignancies; however, developing a safe and effective CAR T-cell approach for solid tumors has remained a challenge.

The CEO and managing director of Chimeric Therapeutics hopes to contribute to the narrative with a handful of offerings in development across 2 platforms: CORE-NK, which uses allogeneic natural killer cells, and T-cell derived autologous therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

SQZ-PBMC-HPV receives FDA Fast Track Designation for patients with advanced or metastatic HPV16+ solid tumors, following promising early results.

The analysis of data from ZUMA-7 demonstrated significant efficacy for axi-cel over second-line standard treatment.

Pivotal phase 3 findings for ofra-vec in patients with ovarian cancer are anticipated in the second half of 2022.

The gene-edited CAR T-cell therapy is currently being investigated in a phase 2 clinical trial.

Tisa-cel was associated with a more favorable safety profile in the analysis.

In this population, median progression-free survival was nearly 40 months.

NKX101 and NKX019 have demonstrated preliminary signs of safety and efficacy in heavily pretreated patients with AML and NHL in 2 separate phase 1 studies.

A phase 1/2 multicenter study is underway following MB-106’s IND approval.

KUR-502 elicited promising response rates for patients with relapsed or refractory B-cell malignancies in a phase 1 study.

The treatment seeks to improve immune reconstitution and graft-versus-leukemia immune response without increasing the risk of GvHD in children and young adults with hematologic malignancies.

Preliminary findings from the phase 1 clinical trial demonstrate good cell persistence and expansion in vivo.

In 37 evaluable patients, the objective response rate in the study was 89% (95% CI, 75%-97%) with complete responses in 78%.

In this late-breaking poster presented at the Tandem Meetings, investigators recommend that patients with primary or secondary central nervous system lymphoma be included in future clinical trials for CAR T-cell therapy.

Armed with an average of 14.3 months of follow-up data, investigators share updates from a cohort in the phase 2 study evaluating cilta-cel in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy at the 2022 Tandem Meetings.

Review top news and interview highlights from the week ending April 15, 2022.

Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm, joins CGTL to discuss the company's development of chimeric co-stimulatory receptor T cells, as well as its clinical programs targeting cancers and infectious diseases.

As patients who undergo CAR T-cell therapy survive longer, more research is required into the long-term neurocognitive effects of this treatment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CT-0508 was granted a fast track designation in September 2021 for use as a potential therapy for patients with solid tumors.

This is the third regenerative medicine advanced therapy designation granted to AlloVir’s posoleucel therapy.